BioHealth Innovation, Inc. Announces Executive Appointments
Sep 14 15
BioHealth Innovation Inc. (BHI) announced that its board of directors has unanimously voted and approved the appointments of board member Juan Carlos Lopez, Ph.D., Head of the Academic Relations and Collaborations (ARC) Group at Roche Pharma Research and Early Development (pRED), and Ex-Officio Board Member Mike Gill, Secretary, Department of Business and Economic Development (DBED), State of Maryland. Dr. Lopez leads the Roche pRED's team in conducting outreach to academic and non-profit biomedical research and healthcare organizations for purposes of enhancing and complementing their internal R&D efforts. Secretary Mike Gill will join the BHI Board in an ex-officio position, bringing with him more than four decades of experience as an entrepreneur, technology executive, investment banker and public servant. Earlier this year, Secretary Gill was tapped by Maryland Governor Larry Hogan to lead the DBED. Prior to his appointment, Secretary Gill led Evergreen Advisors, an investment bank, as chairman and principal. Previously, he founded Hoyt Capital, an investment and advisory firm serving startups and growth companies. Secretary Gill was also a founder First Page, which was acquired by Metrocall; served as chairman of Curtis Engine, a Baltimore power generator company; and was chairman of Bluefire Security Technologies, a mobile cybersecurity developer, from 2006 to 2008.
Tania Fernandez Joins BioHealth Innovation Inc. to Help Manage New BioHealth Gap Fund
Sep 30 14
BioHealth Innovation Inc. announced that venture capitalist, Tania Fernandez, Ph.D., has joined the BHI team as a strategic advisor. Dr. Fernandez will be a member of the management team for a new BioHealth Gap Fund. Dr. Fernandez previously was a venture capitalist with Burrill & Company.
BioHealth Innovation, Inc. Signs Agreement with Roche to Source Technologies for Research, Development and Commercialization
Sep 15 14
BioHealth Innovation Inc. announced that Roche Pharma Research and Early Development (pRED) and the company have entered into an agreement to advance healthcare technologies coming from academic institutions, federal laboratories and startups based in Central Maryland. Under the terms of the agreement, the company will identify health technologies that Roche will evaluate for potential research, development and commercialization opportunities. Priority areas of interest will include oncology, neuroscience, ophthalmology, rare diseases, immunological and infectious diseases. Financial terms for the agreement were not disclosed. The agreement was initiated through Roche pRED Academic Relations and Collaboration group, which is led globally by Juan Carlos Lopez.